Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octreotide microspheres first-line treatment for unresectable locally advanced or metastatic neuroendocrine tumors
ChiCTR2300078850Phase 4Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Dec 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of octreotide LAR in apudoma (NET), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: 24-week clinical benefit rate. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
octreotide LAR
03
Conditions
apudoma (NET)
Beyond the preview
Go deeper on ChiCTR2300078850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078850.